TY - JOUR
T1 - Lesson from nature
T2 - Zataria multiflora nanostructured lipid carrier topical gel formulation against Candida-associated onychomycosis, a randomized double-blind placebo-controlled clinical trial
AU - Moazeni, Maryam
AU - Kelidari, Hamidreza
AU - Nasirzadehfard, Yaser
AU - Shokohi, Tahereh
AU - Roohi, Behrad
AU - Hajheidari, Zohreh
AU - Kazeminejad, Armaghan
AU - Parsay, Shima
AU - Asare-Addo, Kofi
AU - Nokhodchi, Ali
N1 - Funding Information:
This research was supported by Mazandaran University of Medical Sciences (Sari, Iran) [Grant No. 8372]. The current study was conducted in accordance with the ethical guidelines outlined in The Code of Ethics of the World Medical Association (Declaration of Helsinki) regarding experiments involving human subjects. The research protocol received approval from the Ethics Committee of Mazandaran University of Medical Sciences, with the reference number IR.MAZUMS.REC.1397.8372. The study was also registered in the Iranian Registry of Clinical Trials (IRCT) under the code IRCT20210611051539N1, which can be accessed at https://www.irct.ir/. This registration ensures transparency and accessibility of the trial information. Informed consent was obtained from all volunteers, who were also informed of their right to withdraw from the study at any stage without facing any negative consequences. The current study was conducted in accordance with the ethical guidelines outlined in The Code oAcknowledgement_Paraf Ethics of the World Medical Association (Declaration of Helsinki) regarding experiments involving human subjects. The research protocol received approval from the Ethics Committee of Mazandaran University of Medical Sciences, with the reference number IR.MAZUMS.REC.1397.8372. The study was also registered in the Iranian Registry of Clinical Trials (IRCT) under the code IRCT20210611051539N1, which can be accessed at https://www.irct.ir/. This registration ensures transparency and accessibility of the trial information. Informed consent was obtained from all volunteers, who were also informed of their right to withdraw from the study at any stage without facing any negative consequences. This research was supported by Mazandaran University of Medical Sciences (Sari, Iran) [Grant No. 8372].
Funding Information:
This research was supported by Mazandaran University of Medical Sciences (Sari, Iran) [Grant No. 8372].
Publisher Copyright:
© 2024 The Author(s)
PY - 2024/6/1
Y1 - 2024/6/1
N2 - Purpose: The increasing resistance to onychomycosis treatment globally is a major concern as it results in treatment failures. This research aimed to investigate the effectiveness of incorporating nanostructured lipid carriers (NLCs) in a gel formulation for treating mild to moderate Candida-associated onychomycosis using Zataria multiflora (Zt) essential oils. Methods: The characteristics of Zataria multiflora-loaded nanostructured lipid carriers (Zt-NLCs) were validated using a carbopol gel (1 % w/w). In vitro tests were conducted using CLSI M60 standards to evaluate the susceptibility of ten commonly encountered dermatophyte species to antifungal agents. A clinical study was conducted involving 40 volunteers randomly assigned to two groups: one receiving the Zt-NLCs gel and the other receiving a placebo, using a double-blind, placebo-controlled design. The objective was to assess clinical manifestations and mycological findings after topical application for 2 and 4 weeks. The causative agents' species were identified using a PCR-RFLP method. Results: The preparation of Zt-NLCs gel resulted in a uniform suspension of spherical nanoparticles with favourable characteristics and no cytotoxic effects. Zt-NLCs demonstrated significant inhibitory effects on fungal growth and effectively improved clinical and mycological criteria in comparison to the placebo group (p < 0.005), even after 2 weeks of treatment. The C. albicans complex was recognized as the predominant species isolated from the patients using PCR-RFLP. Conclusion: The administration of Zt-NLCs gel for two weeks showed significant efficacy in disease management, as reported by both dermatologists and mycologists and therefore shows its potential use as a treatment against Candidal onychomycosis.
AB - Purpose: The increasing resistance to onychomycosis treatment globally is a major concern as it results in treatment failures. This research aimed to investigate the effectiveness of incorporating nanostructured lipid carriers (NLCs) in a gel formulation for treating mild to moderate Candida-associated onychomycosis using Zataria multiflora (Zt) essential oils. Methods: The characteristics of Zataria multiflora-loaded nanostructured lipid carriers (Zt-NLCs) were validated using a carbopol gel (1 % w/w). In vitro tests were conducted using CLSI M60 standards to evaluate the susceptibility of ten commonly encountered dermatophyte species to antifungal agents. A clinical study was conducted involving 40 volunteers randomly assigned to two groups: one receiving the Zt-NLCs gel and the other receiving a placebo, using a double-blind, placebo-controlled design. The objective was to assess clinical manifestations and mycological findings after topical application for 2 and 4 weeks. The causative agents' species were identified using a PCR-RFLP method. Results: The preparation of Zt-NLCs gel resulted in a uniform suspension of spherical nanoparticles with favourable characteristics and no cytotoxic effects. Zt-NLCs demonstrated significant inhibitory effects on fungal growth and effectively improved clinical and mycological criteria in comparison to the placebo group (p < 0.005), even after 2 weeks of treatment. The C. albicans complex was recognized as the predominant species isolated from the patients using PCR-RFLP. Conclusion: The administration of Zt-NLCs gel for two weeks showed significant efficacy in disease management, as reported by both dermatologists and mycologists and therefore shows its potential use as a treatment against Candidal onychomycosis.
KW - Candida
KW - Clinical trials
KW - Nano-structured lipid carrier
KW - Onychomycosis
KW - Zataria multiflora
UR - http://www.scopus.com/inward/record.url?scp=85189898592&partnerID=8YFLogxK
U2 - 10.1016/j.medidd.2024.100187
DO - 10.1016/j.medidd.2024.100187
M3 - Article
AN - SCOPUS:85189898592
VL - 22
JO - Medicine in Drug Discovery
JF - Medicine in Drug Discovery
SN - 2590-0986
M1 - 100187
ER -